Amulet Capital Partners, a Greenwich, Conn.-based middle-market private equity investment firm focused exclusively on the healthcare sector, acquired Alliance Clinical Network, a Dallas, Texas-based comprehensive clinical site platform.
Financial terms of the transaction were not disclosed.
In partnership with Amulet, ACN intends to strategically expand its footprint – both through continued de novo development and strategic acquisitions – while building on its presence in vaccines and enhancing its capabilities in other therapeutic areas.
ACN currently owns and operates six clinical research sites serving patients, leading pharmaceutical sponsors and contract research organizations (CROs) across three states:
– Hope Clinical Research, Acclaim Clinical Research and 310 Clinical Research in California,
– Excel Clinical Research in Nevada, and
– Epic Clinical Research and Zenos Clinical Research in Texas.
With a focus on Phase II and Phase III general medicine trials and a demonstrated expertise in enrolling diverse patient populations, ACN services a range of clinical therapeutic areas, including dermatology, gastroenterology, neurology, pain, vaccines and women’s health.
ACN will continue to be led by Founder and Chief Executive Officer Anthony Abey, who will retain a significant ownership stake in the business. Since its founding in 2014, ACN has grown rapidly through its innovative tech-enabled business model and unique approach to establishing and developing de novo sites. In 2022, the company supported more than 75 unique clinical trials for 40+ sponsors ranging from emerging biotechs to large pharma.
